Arakena Pharmaceuticals GmbH
Arakena Pharmceuticals GmbH is a Basel-based biopharma start-up with a unique portfolio of potent G protein-coupled receptor kinase (GRK) inhibitors with potential for first-in-class treatment in cardiomyopathies, cardiovascular and metabolic diseases. Cardiomyopathies are responsible for heart failure, sudden cardiac death and hospitalisation due to major cardiovascular events. GRK inhibitors have demonstrated promising efficacy in a range of different heart disease models.
Date, time and room information
May 6, 14:45 - 15:00, room Singapore
Category
Emerging biotech company
Title of the presentation
First-in-class GRK inhibitors for Takotsubo Cardiomyopathy
Speaker information
| Name | Position | Institution |
|---|---|---|
| Oliver Nayler | Co-founder | Arakena Pharmaceuticals GmbH |
